<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="241">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158010</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A03533-36</org_study_id>
    <nct_id>NCT05158010</nct_id>
  </id_info>
  <brief_title>Advancing Tools for Human Early Lifecourse Exposome Research and Translation- Adolescence Follow-up of the HELIX Subcohort</brief_title>
  <acronym>ATHLETE</acronym>
  <official_title>Advancing Tools for Human Early Lifecourse Exposome Research and Translation- Adolescence Follow-up of the HELIX Subcohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ATHLETE will set up a prospective Europe-wide exposome cohort covering the first 2 decades of&#xD;
      the life course, which will integrate data on the external, chemical, physical,behavioral,&#xD;
      and social domains of the exposome, as well as on health outcomes and biological omics&#xD;
      responses, from preconception until adolescence. As part of ATHLETE, the investigators will&#xD;
      follow up a unique existing exposome cohort into adolescence (the HELIX Subcohort).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary biomarkers exposure</measure>
    <time_frame>One week</time_frame>
    <description>Measure of phtalates, phenols, pesticides, (organophosphorus pesticides, metabolites of pyrethroids, 2,4-dichlorophenoxyacid, boscalid, imazalil), cotinine, glycol ethers, polycyclic aromatic hydrocarbon, creatinine, exogenous metabolomics, in a weekly pool of urine collection</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Exposure</condition>
  <condition>Health Behavior</condition>
  <condition>Environment</condition>
  <arm_group>
    <arm_group_label>HELIX's follow-up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HELIX's follow-up</intervention_name>
    <description>Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary&#xD;
Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples.</description>
    <arm_group_label>HELIX's follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For the adolescent :&#xD;
&#xD;
          -  Subject of the EDEN cohort included in the Helix cohort in 2014-2015 in Poitiers&#xD;
             (16-19 years old)&#xD;
&#xD;
          -  Subject benefiting from a Social Security scheme or benefiting through a third party&#xD;
&#xD;
        For the person legally responsible :&#xD;
&#xD;
          -  The legal guardian, if possible the mother, of the adolescent included in Athlete ;&#xD;
&#xD;
          -  Subject benefiting from a Social Security scheme or benefiting through a third person;&#xD;
&#xD;
          -  Free subject, without tutorship or guardianship or subordination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant participation in another clinical research study.&#xD;
&#xD;
          -  Persons not benefiting from a Social Security scheme or not benefiting through a third&#xD;
             party.&#xD;
&#xD;
          -  Adolescents who are incapable or who do not give their consent to follow the study&#xD;
             procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre-Jean SAULNIER, Pr</last_name>
    <phone>05 44 44 46 78</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-jean.saulnier@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>C.H.U. de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole David</last_name>
      <email>carole.david@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Jean Saulnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

